-
The Evolving Landscape of Heart Failure Therapies
Neeta Ratanghayra
January 31, 2024
Heart failure (HF) is a leading cause of disability worldwide and has a major impact on the global economy and healthcare systems.
-
What's happening in HF therapies
Neeta Ratanghayra
January 02, 2024
Heart failure (HF) is a leading cause of disability worldwide and has a major impact on the global economy and healthcare systems.The severity of the disease warrants the development of innovative solutions to address the current treatment gap.
-
Antibody-Drug Conjugates - Lessons Learned
Neeta Ratanghayra
May 20, 2022
Antibody-drug conjugates (ADCs) have made significant progress in tumor therapy and show a promising future.
-
Trends and Developments in HIV Research
Neeta Ratanghayra
March 30, 2022
Novel treatment strategies and advances in care have transformed the lives of people living with HIV (human immunodeficiency virus). Antiretroviral therapy (ART), once-daily single-tablet regimens (STRs)...
-
Bispecific Antibodies – Key Developments in China
Neeta Ratanghayra
August 06, 2021
Bispecific antibodies (BsAbs) are artificially designed antibodies with dual binding sites. The binding sites may be directed at two different antigens or two different epitopes on the same antigen.
-
Alzheimer’s Disease - Recent Advances in Treatment
Neeta Ratanghayra
August 06, 2021
Alzheimer's disease (AD) is a neurodegenerative disease affecting millions of people globally.
-
Antibody-Drug Conjugates – Understanding the "Trojan Horses"
Neeta Ratanghayra
May 31, 2021
A robust strategy for targeted therapy, known as antibody-drug conjugates (ADCs), has been developed to counterfeit this challenge.
-
KRAS - Hot Cancer Target Inhibitors in Developing
Neeta Ratanghayra
March 22, 2021
Mutant oncogenes play a key role in driving cancer progression, and this fact has set the stage for the discovery of targeted anticancer therapies.
-
Biosimilars 2020: Low Approvals, but Significant Advances
Neeta Ratanghayra
March 18, 2021
2020 has been a tough year. The pandemic posed an array of challenges to the healthcare system and the global biopharmaceutical industry both rose to the challenges and seized opportunities.
-
Insights Into the Oncology Landscape in China
Neeta Ratanghayra
December 24, 2020
Significant increases in incidence rates have made cancer a high priority in China. Despite major government reforms to reduce cancer burdens, problems remain. To fulfill its agenda in cancer innovation, China is embracing new frontiers and opportunities.